Powered by

Akashi Therapeutics Presents Positive Clinical Data on HT-100 in Patients with Duchenne Muscular Dystrophy

Jul 03, 2014 - Business Wire

Akashi Therapeutics, Inc ., a clinical stage biopharmaceutical company developing treatments for Duchenne muscular dystrophy , today announced the presentation of preliminary positive clinical data for its most advanced drug candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule developed to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with Duchenne muscular dystrophy (DMD). Preliminary clinical data for HT-100 on the first DMD p...